[{"id":"5077dab5-cc6d-4875-b03f-04b2ac602ed5","acronym":"NFL-BIOPAIN","url":"https://clinicaltrials.gov/study/NCT05781425","created_at":"2023-03-23T14:02:47.910Z","updated_at":"2024-07-02T16:34:37.446Z","phase":"","brief_title":"Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?","source_id_and_acronym":"NCT05781425 - NFL-BIOPAIN","lead_sponsor":"Odense University Hospital","biomarkers":" NEFL","pipe":"","alterations":" ","tags":["NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"},{"id":"c18a797f-f388-457a-8936-39bcb7181e0b","acronym":"MyBrain","url":"https://clinicaltrials.gov/study/NCT05840575","created_at":"2023-05-03T15:04:43.419Z","updated_at":"2024-07-02T16:35:49.160Z","phase":"","brief_title":"Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","source_id_and_acronym":"NCT05840575 - MyBrain","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-05-02"},{"id":"dfc01e34-8b7a-4edc-a08b-c2e3c7075017","acronym":"","url":"https://clinicaltrials.gov/study/NCT05813145","created_at":"2023-04-14T14:03:12.165Z","updated_at":"2024-07-02T16:35:50.588Z","phase":"","brief_title":"Fenofibrate Role in Breast Cancer Patients","source_id_and_acronym":"NCT05813145","lead_sponsor":"Damanhour University","biomarkers":" NEFL","pipe":"","alterations":" ","tags":["NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2023-04-14"},{"id":"de16a910-2705-4a33-b85c-fdf50b60baf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595109","created_at":"2022-10-26T13:56:26.429Z","updated_at":"2024-07-02T16:36:01.816Z","phase":"Phase 2/3","brief_title":"Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients","source_id_and_acronym":"NCT05595109","lead_sponsor":"Tanta University","biomarkers":" TNFA • MPO • NEFL","pipe":"","alterations":" ","tags":["TNFA • MPO • NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 56","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 04/28/2023","primary_completion_date":" 04/28/2023","study_txt":" Completion: 10/28/2024","study_completion_date":" 10/28/2024","last_update_posted":"2022-10-26"},{"id":"07fd8cef-c29a-413c-862a-1abe2245a21c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510856","created_at":"2022-08-26T13:58:43.138Z","updated_at":"2024-07-02T16:36:02.090Z","phase":"Phase 4","brief_title":"Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients","source_id_and_acronym":"NCT05510856","lead_sponsor":"Tanta University","biomarkers":" HMOX1 • NEFL","pipe":"","alterations":" ","tags":["HMOX1 • NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2022-10-20"},{"id":"1ddcbabd-4c83-4f24-a7ec-626b0f1b0228","acronym":"LGI1biom","url":"https://clinicaltrials.gov/study/NCT04001270","created_at":"2022-09-12T10:57:18.426Z","updated_at":"2024-07-02T16:36:58.536Z","phase":"","brief_title":"Core Cerebrospinal Fluid Biomarker Profile in Anti-Leucine Rich Glioma Inactivated 1 (Anti-LGI1) Encephalitis","source_id_and_acronym":"NCT04001270 - LGI1biom","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" NEFL","pipe":"","alterations":" ","tags":["NEFL"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 08/15/2019","primary_completion_date":" 08/15/2019","study_txt":" Completion: 11/15/2019","study_completion_date":" 11/15/2019","last_update_posted":"2019-06-28"}]